AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

Consequently, the early literature reporting cataract surgery routinely documented the mortality rate (secondary to pulmonary emboli ... is focused on the retina. These complex lenses are ...

Patients without diabetes using GLP-1RAs are less likely to develop glaucoma compared with those who use other weight loss therapies.

Issuing a draft list of revised risk-based classification of cardiovascular and neurological devices, the Central Drugs ...

A left ventricular thrombus following a heart attack is considered a very serious complication because of the risk the clot will travel to the brain and cause a stroke or a systemic embolism.

Based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death vs. neoadjuvant chemotherapy alone WILMINGTON, Del.

AstraZeneca's IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

Serious adverse reactions occurred in 24% of patients; the most frequent (≥1%) serious adverse reactions were pulmonary embolism (1.9%), febrile neutropenia (1.5%), acute kidney injury (1.3% ...

Thus, the clinical manifestation depends on the number of organs affected, the composition of the emboli, and the quantity of the embolus expelled from the atherosclerotic plaque. An isolated ...